DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Guturi, Naidu ^a   Sarkar, Moumita ^a   Bhowmik, Arijit ^a   Das, Nilanjana ^a   Ghosh, Kanti ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN 2; BETA CATENIN; CYCLIN D1; DEAD BOX PROTEIN; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN; PROTEIN P68; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VIMENTIN; WNT3A PROTEIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; DDX5 PROTEIN, HUMAN; DDX5 PROTEIN, MOUSE; MESSENGER RNA; TCF4 PROTEIN, HUMAN; TCF4 PROTEIN, MOUSE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CONTROL; CANCER GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; UPREGULATION; WNT SIGNALING PATHWAY; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; DISEASE COURSE; FEMALE; GENETICS; HEK293 CELL LINE; MCF 7 CELL LINE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DEAD-BOX RNA HELICASES; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84924262064     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0496-5     Document Type: Article

References (64)

1. Brennan KR, Brown AMC: Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004, 9:119-131.
2. Lin S-Y, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG: Hung M-C: β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000, 97:4262-4266.
3. Prosperi JR, Goss KH: A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 2010, 11:1074-1088.
4. Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Ellenson LH, Kitajewski J: APC truncation and increased β-catenin levels in a human breast cancer cell line. Carcinogenesis 2000, 21:1453-1456.
5. Zhang J, Li Y, Liu Q, Lu W, Bu G: Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 2010, 29:539-549.
6. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R: Reis-Filho JS: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011, 24:209-231.
7. Jönsson M, Borg A, Nilbert M, Andersson T: Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer Oxf Engl 1990 2000, 36:242-248.
8. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, Brisken C: Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A 2006, 103:3799-3804.
9. Benhaj K, Akcali KC, Ozturk M: Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 2006, 15:701-707.
10. Howe LR, Brown AMC: Wnt signaling and breast cancer. Cancer Biol Ther 2004, 3:36-41.
11. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF: Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 2004, 25:1337-1342.
12. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan Y-C, Deng X, Chen L, Kim CCH, Lau S, Somlo G, Yen Y: FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011, 30:4437-4446.
13. Liu C-C, Prior J, Piwnica-Worms D, Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci 2010, 107:5136-5141.
14. Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O, Emi M: Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci 2003, 94:515-518.
15. Klarmann GJ, Decker A, Farrar WL: Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008, 3:59-63.
16. Suzuki H, Toyota M, Caraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T: Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008, 98:1147-1156.
17. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006, 25:3479-3488.
18. Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A: Study of phospho-β-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 2006, 19:556-563.
19. Lane DP, Hoeffler WK: SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature 1980, 288:167-170.
20. Ford MJ, Anton IA, Lane DP: Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature 1988, 332:736-738.
21. Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshida I, Yoshimura K, Mihara M, Naitou M, Endoh H, Nakamura T, Akimoto C, Yamamoto Y, Katagiri T, Foulds C, Takezawa S, Kitagawa H, Takeyama K, O'Malley BW, Kato S: DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 2007, 9:604-611.
22. Abdelhaleem M: RNA helicases: regulators of differentiation. Clin Biochem 2005, 38:499-503.
23. Fuller-Pace FV: DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 2006, 34:4206-4215.
24. Rossler OG, Straka A, Stahl H: Rearrangement of structured RNA via branch migration structures catalysed by the highly related DEAD-box proteins p68 and p72. Nucleic Acids Res 2001, 29:2088-2096.
25. Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F: Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115:751-763.
26. Watanabe M, Yanagisawa J, Kitagawa H, Takeyama K, Ogawa S, Arao Y, Suzawa M, Kobayashi Y, Yano T, Yoshikawa H, Masuhiro Y, Kato S: A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor α coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J 2001, 20:1341-1352.
27. Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN: The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 2008, 68:7938-7946.
28. Bates GJ, Nicol SM, Wilson BJ, Jacobs A-MF, Bourdon J-C, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV: The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 2005, 24:543-553.
29. Caretti G, Schiltz RL, Dilworth FJ, Padova MD, Zhao P, Ogryzko V, Fuller-Pace FV, Hoffman EP, Tapscott SJ, Sartorelli V: The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell 2006, 11:547-560.
30. Shin S, Rossow KL, Grande JP, Janknecht R: Involvement of RNA Helicases p68 and p72 in Colon Cancer. Cancer Res 2007, 67:7572-7578.
31. Yang L, Lin C, Liu Z-R: P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing axin from β-catenin. Cell 2006, 127:139-155.
32. Yang L, Lin C, Zhao S, Wang H, Liu Z-R: Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 2007, 282:16811-16819.
33. Jacobs A-M, Nicol SM, Hislop RG, Jaffray EG, Hay RT, Fuller-Pace FV: SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene 2007, 26:5866-5876.
34. Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, Steele RJ, Fuller-Pace FV: Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. 20. Oncogene 2001, 20:7734-7743.
35. Mooney SM, Grande JP, Salisbury JL, Janknecht R: Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry (Mosc) 2010, 49:1-10.
36. Beier UH, Maune S, Meyer JE, Görögh T: Overexpression of p68 mRNA in head and neck squamous cell carcinoma cells. Anticancer Res 2006, 26:1941-1946.
37. Stevenson RJ, Hamilton SJ, MacCallum DE, Hall PA, Fuller-Pace FV: Expression of the "DEAD box" RNA helicase p68 is developmentally and growth regulated and correlates with organ differentiation/maturation in the fetus. J Pathol 1998, 184:351-359.
38. Bhattacharya S, Ghosh MK: HAUSP, a novel deubiquitinase for Rb - MDM2 the critical regulator. FEBS J 2014, 281:3061-3078.
39. Carter CL, Lin C, Liu C-Y, Yang L, Liu Z-R: Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter. Oncogene 2010, 29:5427-5436.
40. Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK: The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 2013, 32:1284-1295.
41. Guturi KKN, Mandal T, Chatterjee A, Sarkar M, Bhattacharya S, Chatterjee U, Ghosh MK: Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cells. J Biol Chem 2012, 287:18287-18296.
42. Sha J, Ghosh MK, Zhang K, Harter ML: E1A interacts with Two opposing transcriptional pathways to induce quiescent cells into S phase. J Virol 2010, 84:4050-4059.
43. Bhowmik A, Das N, Pal U, Mandal M, Bhattacharya S, Sarkar M, Jaisankar P, Maiti NC, Ghosh MK: 2,2'-diphenyl-3,3'-diindolylmethane: a potent compound induces apoptosis in breast cancer cells by inhibiting EGFR pathway. PLoS One 2013, 8:e59798.
44. Mandal T, Bhowmik A, Chatterjee A, Chatterjee U, Chatterjee S, Ghosh MK: Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2 - Protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells. Cell Signal 2014, 26:1725-1734.
45. Chatterjee A, Chatterjee U, Ghosh MK: Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer. Cell Death Dis 2013, 4:e543.
46. GraphPad QuickCalcs. [http://www.graphpad.com/quickcalcs/index.cfm ]
47. Yang L, Lin C, Liu Z-R: Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Mol Cancer Res 2005, 3:355-363.
48. Mastracci TL, Tjan S, Bane AL, O'Malley FP, Andrulis IL: E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005, 18:741-751.
49. Wang D, Huang J, Hu Z: RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics 2012, 11:M111.011932.
50. Yang S-Z, Kohno N, Yokoyama A, Kondo K, Hamada H, Hiwada K: Decreased E-cadherin augments β-catenin nuclear localization: Studies in breast cancer cell lines. Int J Oncol 2001, 18:541-548.
51. Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I: Upregulation of TCF4 expression as a transcriptional target of β-catenin/p300 complexes during trans-differentiation of endometrial carcinoma cells. Lab Invest 2005, 85:768-779.
52. Mosimann C, Hausmann G, Basler K: Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009, 10:276-286.
53. Kahlina K, Goren I, Pfeilschifter J, Frank S: p68 DEAD Box RNA helicase expression in keratinocytes regulation, nucleolar localization, and functional connection to proliferation and vascular endothelial growth factor gene expression. J Biol Chem 2004, 279:44872-44882.
54. Liu J, Ding X, Tang J, Cao Y, Hu P, Zhou F, Shan X, Cai X, Chen Q, Ling N, Zhang B, Bi Y, Chen K, Ren H, Huang A, He T-C, Tang N: Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One 2011, 6:e27496.
55. Paul I, Bhattacharya S, Chatterjee A, Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013, 4:427-446.
56. Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS, Stillman B: DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov 2012, 2:812-825.
57. Li Z, Calcar SV, Qu C, Cavenee WK, Zhang MQ, Ren B: A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci 2003, 100:8164-8169.
58. Menssen A, Hermeking H: Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci 2002, 99:6274-6279.
59. Rössler OG, Hloch P, Schütz N, Weitzenegger T, Stahl H: Structure and expression of the human p68 RNA helicase gene. Nucleic Acids Res 2000, 28:932-939.
60. Nelson WJ, Nusse R: Convergence of Wnt, ß-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
61. Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28:151-166.
62. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18:2883-2891.
63. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, Randazzo F, Gundel R, Warren RS, Escobedo J, Aukerman SL, Taylor RN: Fantl WJ: beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 2003, 63:3145-3153.
64. Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A: Postigo A: β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 2011, 108:19204-19209.